

Anti-ASAP1 [7B12]

Catalogue number: 151767

Sub-type: Primary antibody

Images:

Contributor

Inventor: Jonathan Sleeman

Institute: Karlsruhe Institute of Technology

Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: Anti-ASAP1 [7B12]

Alternate name:

Class: Monoclonal

Conjugate: Unconjugated

Description: ASAP1 possesses phosphatidylinositol 4,5-biphosphate-dependent GTPase-activating protein activity for ARF1 (ADP ribosylation factor 1) and ARF5 and a lesser activity towards ARF6. It may coordinate membrane trafficking with cell growth or actin cytoskeleton remodeling by binding to both SRC and PIP2. It potentially has involvement in tumour progression, having been shown to promote metastasis formation in vivo and stimulate tumor cell motility, invasiveness, and adhesiveness in vitro. ASAP1 represents a potential target for cancer therapy.

Purpose:

Parental cell:

Organism:

Tissue:

Model:

Gender:

Isotype: IgG2b

Reactivity: Human ; Rat

Selectivity:

Host: Mouse

Immunogen: Recombinant Protein (fragment of human ASAP1 (corresponding nucleotides 977-1532 of KIAA1249) with N-terminal GST tag produced in E.coli strain BL-21)

Immunogen UNIPROT ID:

Sequence:

Growth properties:

Production details:

Formulation:

Recommended controls: Human: HT29 and MDA-MB-231 Rat: ASAP1 is strongly expressed in ASML and weakly expressed in 1AS pancreatic carcinoma cells.

Bacterial resistance:**Selectable markers:****Additional notes:**

Target details

Target: ASAP1

Target alternate names:

Target background: ASAP1 possesses phosphatidylinositol 4,5-biphosphate-dependent GTPase-activating protein activity for ARF1 (ADP ribosylation factor 1) and ARF5 and a lesser activity towards ARF6. It may coordinate membrane trafficking with cell growth or actin cytoskeleton remodeling by binding to both SRC and PIP2. It potentially has involvement in tumour progression, having been shown to promote metastasis formation in vivo and stimulate tumor cell motility, invasiveness, and adhesiveness in vitro. ASAP1 represents a potential target for cancer therapy.

Molecular weight:**Ic50:**

Applications

Application: IHC ; WB ; ELISA ; IHC ; IP ; WB

Application notes:

Handling

Format: Liquid

Concentration: 0.84 mg/ml

Passage number:

Growth medium:

Temperature:

Atmosphere:

Volume:

Storage medium:

Storage buffer: PBS with 0.02% azide

Storage conditions: -15° C to -25° C

Shipping conditions: Shipping at 4° C

Related tools

Related tools:

References

References:

CancerTools.org